Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat

Journal of Neuro-Oncology

Volumn 42, Issue 1, 1999, Pages 13-21

  Bergström, Per ^a   Johnsson, A ^b   Bergenheim, T ^a   Henriksson, R ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amifostine; Chemotherapy; Cisplatin; DNA adducts; Glioma

Indexed keywords

AMIFOSTINE; CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA ADDUCT; GLIOBLASTOMA; GLIOMA; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CELL; KIDNEY CORTEX; MALNUTRITION; NEPHROTOXICITY; NONHUMAN; RAT; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION;

AMIFOSTINE; ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE; CISPLATIN; DNA ADDUCTS; GLIOMA; KIDNEY; KIDNEY CORTEX; RATS; RATS, INBRED STRAINS;

EID: 0032962473     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006152103476     Document Type: Article

References (32)

1. Spencer CM, Goa KL: Amifostine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50(6): 1001-1031, 1995
2. Budd GT, Bukowski RM, Murthy S, Adelstein D, Pelley D, Olencki T, Petrus J, Lorenzi V, McLain D, Egorin M, Conlon J, Graden D, Reynolds R: Randomized trial of carboplatin (CBDCA) vs CBDCA + amifostine (AMI) in advanced malignancy (abstract 1524). Proc Am Soc Cancer Oncol 13: 442, 1994
3. Glick J, Kemp G, Rose P, Mitchell E, Reynolds R, Scheffler B, Capizzi R: A randomized trial of cyclophosphamide and cisplatin ± amifostine in the treatment of advanced epithelial ovarian cancer (abstract 1485). Proc Am Soc Clin Oncol 13: 432, 1994
4. Glover D, Glick JK, Weiler C, Hurowitz S, Kligerman MM: WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 4: 584-588, 1986
5. Poplin EA, LoRosso P, Lokich JJ, Gullo JJ, Leming PD, Schultz JJ, Veach SR, McCulloch W, Baker L, Schein P: Randomized clinical trial of mitomycin C with or without pretreatment with WR2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415-419, 1994
6. Glover D, Grabelsky S, Fox K, Weiler C, Cannon L, Glick J: Clinical trials of WR-2721 and cis-platinum. Int J Radiat. Oncol Biol Phys 16: 1201-1204, 1989
7. Glover D, Glick JK, Weiler C, Fox K, Turrisi A, Kligerman MM: Phase I/II trials of WR-2721 and cis-platinum. Int J Oncol Biol Phys 12: 1509-1512, 1986
8. Avril MF, Ortoli JC, Fortier-Beaulieu M, Turz T, Guillaume JC, McCulloch W, Toy J, Schein P: High dose cisplatin (c) and WR2721 in metastatic melanoma (abstract 1181). Proc Am Soc Clin Oncol 11: 344, 1992
9. Jordan SW, Yuhas JM, Glick J: Modulation of cis-platinum renal toxicity by the radioprotective agent WR2721. Exp Mol Pathol 36: 297-305, 1982
10. Treskes M, Boven M, Holwerda U, Pinedo HM, van der Vijgh WJ: Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 52: 2257-2260, 1992
11. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, van der Vijgh WJ: Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithiocarbamate. Biochem Pharmacol 43: 1013-1019, 1992
12. Stewart DJ, Molepo JM, Eapen L, Montpetit VA, Goel R, Wong PT, Popovic P, Taylor KD, Raaphorst GP: Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys 28: 531-542, 1994
13. Laerum OD, Rajewsky MF, Schachner M, Stavrou D, Haglid KG, Haugen Å: Phenotypic properties of neoplastic cell lines developed from fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. Zellular Krebsforschung 89: 273-295, 1977
14. Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Ståhl E: Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cipslatin-DNA adducts. Cancer Chemother Pharmacol 37: 23-31, 1995
15. Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, Engelse I: Immunocytochemical detection of interaction products of cis-diaminedichloro-platinum (II) and cis-diammine (1,1-cyclobutanedicarboxylato) platinum (II) with DNA in rodent tissues. Cancer Res 47: 6719-6725, 1987
16. Johnsson A, Olsson C, Andersson H, Cavallin-Ståhl E: Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 17: 142-150, 1994
17. Bacus JW, Grace LJ: Optical microscope system for standardized cell measurements and analyses. Applied Optics 26: 3280-3293, 1987
18. Bergström P, Johnsson A, Cavallin-Ståhl E, Bergenheim T, Henriksson R: Effects of Amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissue in rat. Eur J Cancer 33(1): 153-159, 1997
19. Washburn LC, Carlton JE, Hayes RL: Distribution of WR-2721 in normal and malignant tissues of mice and rats bearing solid tumors: dependence on tumour type, drug, dose and species. Radiat Res 59: 475-483, 1974
20. 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 68: 284-291, 1976
21. Korst AEC, Boven E, van der Sterre MLT, Fichtinger-Schepman AMJ, van der Vijgh WJF: Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. Eur J Cancer 34(3): 412-416, 1998
22. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC: Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 48: 3634-3640, 1988
23. Lauk S, Denekamp J: Identification of vasculature. Enzyme histochemistry. Gray laboratory annual report 56, 1985
24. Kennedy KA, Reicher BA, Rockwell S, Sartorelli JR. In: AC Sartorelli, JR Bertino, J Slazo (eds) Molecular Targets and Actions for Cancer Chemotherapeutic Agents. Academic press, New York, 1981, pp 85-101
25. Vaupel PW, Frinak S, Bicher HI: Heterogenous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res 41: 2008-2013, 1981
26. Mies G, Paschen W, Csiba L, Krajewski S, Wechsler W, Hossman KA: Comparison of regional tissue pH measured with the umbelliferone and 14C-DMO technique in rat brain. J Cereb Blood Flow Metab 19 (suppl): 247-248, 1985
27. Rottenberg DA, Ginos JZ, Kearfott KJ, Junck L, Bigner DD: In vivo measurement of regional brain tissue pH using positron emission tomography. Ann Neurol 15 (suppl): 98-102, 1984
28. Vaupel P, Kallinowski F, Adams GE: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989
29. Steiger E, Oram-Smith J, Miller E, Kuo L, Vars HM: Effects of nutrition on tumour growth and tolerance to chemotherapy. J Surg Res 18: 455-461, 1975
30. Daly JM, Reynolds HM, Rowlands BJ, Dudrick SJ, Copeland EM: Tumour growth in Experimental animals. Nutritional manipulation and chemotherapeutic response in the rat. Ann Surg 191: 316-322, 1980
31. Daly JM, Copeland EM, Dudrick SS, Delaney MS: Nutritional repletion of malnourished tumour-bearing and nontumor-bearing rats: effects on body weight, liver, muscle and tumour. J Surg Res 28: 507-518, 1980
32. Karpeh MS, Kehne JA, Seung Hoon Choi BS, Ziegler MM: Tumour immunogenicity, nutritional repletion and cancer. Surgery 102: 283-290, 1987.